Clinical and Microbiologic Characteristics of Cephalosporin-Resistant E. Coli-PITT Protocol
This trial is active, not recruiting.
|Condition||e coli infections|
|Sponsor||University of Pittsburgh|
|Collaborator||Merck Sharp & Dohme Corp.|
|Start date||March 2009|
|End date||December 2016|
|Trial size||150 participants|
|Trial identifier||NCT00877708, IRB#PRO08100393|
The purpose of this study is to review patients with E. coli infections at UPMC from September 1, 2008 to August 31, 2010 to determine if these infections have arisen in the community rather than in hospitals or nursing homes and determine their clinical outcomes.
The specific aims of this study are to:
1. Review whether cephalosporin-resistant E. coli infections are hospital-acquired, healthcare-associated or community-associated.
2. Determine the clinical outcome of the patients according to the antibiotics given.
|Observational model||case control|
dead or alive
time frame: end of study
Male or female participants at least 18 years old.
Inclusion Criteria: - patients with E. coli infections at UPMC Exclusion Criteria: - not meeting entry criteria
|Official title||Clinical and Microbiologic Characteristics of Cephalosporin-Resistant E. Coli-PITT Protocol|
|Principal investigator||Yohei Doi, MD|
|Description||De-identified data will be obtained by the honest broker for the requested time period. In addtion, the honest broker will work with the microbiology laboratory to collect the isolates associated with the de-identified data. All data and samples will be de-identified. De-identified data will be given to the nurse coordinator to complete the case report forms and enter the data into the password protected database and the de-identified isolates will be stored and analyzed on the 8th floor Scaife in Dr. Yohie Doi's laboratory.|
Call for more information